Printer Friendly

Kissei Enters Development and Sales Agreement with Pneuma Partners LLC on Calfactant.

Tokyo, Japan, Jan 15, 2008 - (JCN) - Kissei Pharmaceutical today announced that it entered an agreement with New York-based Pneuma Partners LLC concerning research, development and marketing for Calfactant in Japan. Calfactant is now under development by Pneuma in the US.

Kissei will attempt to get an early approval of Calfactant for the indication of Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS) utilizing the results of phase III clinical trial which will be conducted by Pneuma in the US.

ALI and its severe form, ARDS, are types of lung failures resulting from pneumonia, pulmonary injury, etc. There is no effective therapeutic medication for ARDS at present. About 40,000 patients are affected with ALI/ARDS every year in Japan and 30-40% of those patients pass away despite the very best care in the ICU.

JCN Newswire. All rights reserved. A division of Japan Corporate News Network K.K.
COPYRIGHT 2008 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2008, Gale Group. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCNN News Summaries
Date:Jan 15, 2008
Words:150
Previous Article:Novartis Pharma, Mitsubishi Tanabe Pharma Revise Cooperation HMG-GoA Reductase Inhibitor Lochol(R).
Next Article:Komatsu to Deliver Autonomous Haulage System, Flagship 930E-4 to Rio Tinto.


Related Articles
Nicodemus's stupid question & the Source of Life: a poetic reflection of what God does for humankind from the Gospel that soars. (Word Alive).
Kissei Pharmaceutical, JCR Pharmaceuticals Enter into Joint Research Agreement for JR-013, Recombinant Human Erythropoietin-based Renal Anemia Agent.
Kissei Pharmaceutical to License KGA, Diabetes Drug Candidate, to GlaxoSmithKline.
Kissei Pharmaceutical, Daiichi Pharmaceutical Jointly Launch Urination Disorder Improving Drug.
Somerset commits $300m to luxury Fisher Island project.
Kissei and Eisai Sign a License Agreement to Develop and Commercialize Glufast(R), a Rapid-acting Insulin Secretagogue in 10 ASEAN Countries.
Kissei, Nuon Therapeutics Enter Agreement on Transilast.
Kissei and Eisai Sign License Agreement to Develop and Commercialize Glufast(R), a Rapid-acting Insulin Secretagogue in China.
Kissei Announces New Drug Application for Silodosin has been Filed with FDA.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters